UY26148A1 - NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS - Google Patents
NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORSInfo
- Publication number
- UY26148A1 UY26148A1 UY26148A UY26148A UY26148A1 UY 26148 A1 UY26148 A1 UY 26148A1 UY 26148 A UY26148 A UY 26148A UY 26148 A UY26148 A UY 26148A UY 26148 A1 UY26148 A1 UY 26148A1
- Authority
- UY
- Uruguay
- Prior art keywords
- disorders
- nos
- sleep
- inhibitors
- sleep disorders
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 3
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000019116 sleep disease Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 201000004569 Blindness Diseases 0.000 abstract 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 abstract 1
- 208000008967 Enuresis Diseases 0.000 abstract 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006199 Parasomnias Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000010340 Sleep Deprivation Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 206010020765 hypersomnia Diseases 0.000 abstract 1
- 230000001788 irregular Effects 0.000 abstract 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract 1
- 201000003631 narcolepsy Diseases 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 208000005346 nocturnal enuresis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 208000012672 seasonal affective disease Diseases 0.000 abstract 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 230000008454 sleep-wake cycle Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a nuevos usos farmacéuticos para compuestos que presentan actividad como inhibidores de la óxido nítrico sintasa (NOS). Específicamente, se refiere al uso de inhibidores de la NOS particularmente de inhibidores selectivos de la Nos neuronal (nNos), solos o en combinación con otro agente activo, en particular, un SSRI o un antagonista del receptor NK-1, para el tratamiento de trastornos o afecciones cuyo tratamiento puede realizarse o facilitarse mediante la alteración de los ritmos circadianos. Son ejemplos de tales trastornos y afecciones la ceguera, la obesidad, el trastorno afectivo estacional, el trastorno bipolar, el desfase horario, trastornos de los ritmos circadianos del sueno, privación de sueno, parasomnias, trastornos del sueno REM, hipersomnia, trastornos de los ciclos de sueno-vigilia, narcolepsia y trastornos del sueno asociados con el trabajo a turnos o con horarios de trabajo irregulares; enuresis nocturna y síndrome de las piernas inquietas.The present invention relates to novel pharmaceutical uses for compounds exhibiting activity as nitric oxide synthase (NOS) inhibitors. Specifically, it refers to the use of NOS inhibitors, particularly selective inhibitors of neuronal Nos (nNos), alone or in combination with another active agent, in particular, an SSRI or an NK-1 receptor antagonist, for the treatment of disorders or conditions whose treatment can be performed or facilitated by altering circadian rhythms. Examples of such disorders and conditions are blindness, obesity, seasonal affective disorder, bipolar disorder, jet lag, circadian rhythm sleep disorders, sleep deprivation, parasomnias, REM sleep disorders, hypersomnia, sleep-wake cycles, narcolepsy, and sleep disorders associated with shift work or irregular work schedules; nocturnal enuresis and restless legs syndrome.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13552099P | 1999-05-21 | 1999-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26148A1 true UY26148A1 (en) | 2000-12-29 |
Family
ID=22468464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26148A UY26148A1 (en) | 1999-05-21 | 2000-05-18 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1178784A1 (en) |
JP (1) | JP2003523941A (en) |
KR (1) | KR20020010916A (en) |
CN (1) | CN1617743A (en) |
AP (1) | AP2001002326A0 (en) |
AR (1) | AR022640A1 (en) |
AU (1) | AU2935300A (en) |
BG (1) | BG106208A (en) |
BR (1) | BR0010820A (en) |
CA (1) | CA2374668A1 (en) |
CO (1) | CO5160295A1 (en) |
DZ (1) | DZ3041A1 (en) |
EA (1) | EA200101110A1 (en) |
EE (1) | EE200100611A (en) |
GT (1) | GT200000071A (en) |
HN (1) | HN2000000045A (en) |
HR (1) | HRP20010862A2 (en) |
HU (1) | HUP0301287A3 (en) |
IL (1) | IL145955A0 (en) |
IS (1) | IS6126A (en) |
MA (1) | MA26732A1 (en) |
MX (1) | MXPA01011978A (en) |
NO (1) | NO20015651L (en) |
OA (1) | OA11943A (en) |
PA (1) | PA8494601A1 (en) |
PE (1) | PE20010157A1 (en) |
PL (1) | PL358538A1 (en) |
SK (1) | SK16602001A3 (en) |
TN (1) | TNSN00106A1 (en) |
TR (1) | TR200103351T2 (en) |
UY (1) | UY26148A1 (en) |
WO (1) | WO2000071107A2 (en) |
ZA (1) | ZA200109555B (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10001785A1 (en) * | 2000-01-18 | 2001-07-19 | Boehringer Ingelheim Pharma | Use of NK-1 receptor antagonists for treatment of restless legs syndrome |
GB0019006D0 (en) * | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
US6803470B2 (en) * | 2001-10-10 | 2004-10-12 | Pfizer Inc | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines |
DOP2002000467A (en) * | 2001-10-10 | 2003-04-15 | Pfizer Prod Inc | 2-AMINO-6 (PHENYL REPLACED IN POSITIONS 2,4,5) -PIRIDINES |
CN100368409C (en) * | 2003-06-24 | 2008-02-13 | 神经研究公司 | Novel 8-aza-bicyclo not 3.2.1|octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
EP1634598A1 (en) * | 2004-09-07 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Use of piperazine derivatives and analogues for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
EP2152271B1 (en) | 2007-06-08 | 2015-10-21 | Janssen Pharmaceutica, N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine/Piperazine derivatives |
WO2008148851A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
CN101678019B (en) | 2007-06-08 | 2016-03-30 | 詹森药业有限公司 | Piperidine/piperazine derivatives |
WO2009147170A2 (en) | 2008-06-05 | 2009-12-10 | Janssen Pharmaceutica Nv | Drug combinations comprising a dgat inhibitor and a ppar-agonist |
WO2010101246A1 (en) | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
EP3983392A4 (en) * | 2019-06-14 | 2023-12-06 | SRX Cardio, LLC | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9) |
-
2000
- 2000-03-16 AP APAP/P/2001/002326A patent/AP2001002326A0/en unknown
- 2000-03-16 CA CA002374668A patent/CA2374668A1/en not_active Abandoned
- 2000-03-16 BR BR0010820-0A patent/BR0010820A/en not_active IP Right Cessation
- 2000-03-16 OA OA1200100301A patent/OA11943A/en unknown
- 2000-03-16 EE EEP200100611A patent/EE200100611A/en unknown
- 2000-03-16 PL PL00358538A patent/PL358538A1/en not_active Application Discontinuation
- 2000-03-16 KR KR1020017014884A patent/KR20020010916A/en not_active Application Discontinuation
- 2000-03-16 WO PCT/IB2000/000295 patent/WO2000071107A2/en not_active Application Discontinuation
- 2000-03-16 AU AU29353/00A patent/AU2935300A/en not_active Abandoned
- 2000-03-16 IL IL14595500A patent/IL145955A0/en unknown
- 2000-03-16 TR TR2001/03351T patent/TR200103351T2/en unknown
- 2000-03-16 JP JP2000619414A patent/JP2003523941A/en not_active Withdrawn
- 2000-03-16 HU HU0301287A patent/HUP0301287A3/en unknown
- 2000-03-16 MX MXPA01011978A patent/MXPA01011978A/en unknown
- 2000-03-16 EP EP00907891A patent/EP1178784A1/en not_active Ceased
- 2000-03-16 SK SK1660-2001A patent/SK16602001A3/en unknown
- 2000-03-16 EA EA200101110A patent/EA200101110A1/en unknown
- 2000-03-16 CN CNA008078785A patent/CN1617743A/en active Pending
- 2000-04-04 HN HN2000000045A patent/HN2000000045A/en unknown
- 2000-04-04 CO CO00024427A patent/CO5160295A1/en unknown
- 2000-04-25 PA PA20008494601A patent/PA8494601A1/en unknown
- 2000-05-17 TN TNTNSN00106A patent/TNSN00106A1/en unknown
- 2000-05-17 DZ DZ000084A patent/DZ3041A1/en active
- 2000-05-17 GT GT200000071A patent/GT200000071A/en unknown
- 2000-05-17 MA MA25976A patent/MA26732A1/en unknown
- 2000-05-18 UY UY26148A patent/UY26148A1/en not_active Application Discontinuation
- 2000-05-19 AR ARP000102387A patent/AR022640A1/en not_active Application Discontinuation
- 2000-05-19 PE PE2000000473A patent/PE20010157A1/en not_active Application Discontinuation
-
2001
- 2001-10-26 IS IS6126A patent/IS6126A/en unknown
- 2001-11-20 ZA ZA200109555A patent/ZA200109555B/en unknown
- 2001-11-20 NO NO20015651A patent/NO20015651L/en not_active Application Discontinuation
- 2001-11-20 HR HR20010862A patent/HRP20010862A2/en not_active Application Discontinuation
- 2001-12-11 BG BG06208A patent/BG106208A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26148A1 (en) | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | |
HN2000000020A (en) | INHIBITORS OF THE RECOVERY OF MONOAMINS FOR THE TREATMENT OF CNS DISORDERS. | |
UY29321A1 (en) | PIPERAZINILUREAS AND PIPERIDINILUREAS AS AMID HYDROLASSES MODULATORS OF FATTY ACIDS | |
AR060836A1 (en) | A TRANS-MUCOSA DISK TO ADMINISTER AN ACTIVE AGENT, A TRANS-MUCOSA COMPOSITION AND THE METHOD OF ADMINISTRATION OBTAINED | |
CL2009000816A1 (en) | Methods to modify a specific structure associated with a biological activity; and its use in the treatment of diseases and symptoms such as autoimmune, ocular, CNS, cancer, among others. | |
CO5670327A2 (en) | PROCEDURE FOR THE TREATMENT OF DEPRESSION AND ANXIETY DISORDERS THROUGH COMBINATION THERAPY | |
AR043356A1 (en) | SUSTAINED RELEASE DEVICE FOR THE OCULAR ADMINISTRATION OF CARBON ANHYDRATION INHIBITORS AND USE OF CARBON ANHYDRATION INHIBITORS FOR PREPARATION | |
CR6616A (en) | NEW USEFUL BIARILETER DERIVATIVES AS INHIBITORS OF MONOAMINAS RECAPTATION | |
AR080143A1 (en) | PIRROLIDINA-2-SUBSTITUTED CARBOXAMIDS, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE TREATMENT OF ONCOLOGICAL DISORDERS | |
CR10166A (en) | USE OF BENZO-FUSION HETEROCICLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF BIPOLAR DISORDER AND MANIA | |
AR059501A1 (en) | USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT | |
CR8928A (en) | ARILSULPHONYLESTILBEN DERIVATIVES FOR INSOMNIA TREATMENT AND RELATED AFFECTIONS | |
ES2150671T3 (en) | COMPOSITE OF BENCIMIDAZOL AND ITS USE AS MODULATORS OF THE GABA-A RECEIVER COMPLEX. | |
PE20221730A1 (en) | CYCLOALKYLUREA DERIVATIVE | |
AR088267A1 (en) | DERIVATIVES, OF THE BLOOD COAGULATION FACTORS VII AND VIIA, CONJUGATES AND COMPLEXES THAT INCLUDE THE SAME AND ITS USES | |
BRPI0514397A (en) | 3-arylthioindole-2-carboxamide derivatives and analogues thereof as inhibitors of casein kinase epsilon | |
CL2021003032A1 (en) | Methods of treating chronic spontaneous urticaria using a Bruton's tyrosine kinase inhibitor. | |
RU2008148597A (en) | PHARMACEUTICAL COMBINATIONS | |
AR053780A1 (en) | USE OF MIRTAZAPINE S FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF BOCHORNOS | |
AR067450A1 (en) | PHARAMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF A TRIAZOLOBENZODIAZEPIN AND A SELECTIVE INHIBITING AGENT OF SEROTONINE RECAPTURE | |
ECSP003483A (en) | NEW PHARMACEUTICAL COMBINATIONS FOR HOS INHIBITORS | |
PA8479801A1 (en) | NEW PHARMACEUTICAL USES FOR US INHIBITORS | |
CL2008003140A1 (en) | Compounds derived from 5-alkoxy-2,3-dihydro-benzofuran-3-yl-alkyl acylated amines with activity at the mt1 and mt2 receptors; pharmaceutical composition; and use in the treatment of depression, insomnia, fatigue associated with "jet lag", psychotic diseases, epilepsy, sleep disorders, Parkinson's, Alzheimer's, among others. | |
AR043735A1 (en) | A COMPOSITION FOR HAIR CARE | |
Palaniyappan et al. | Antidepressants: will new mechanisms of action improve poor outcomes? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20110617 |